Health By Anna Gorman — Kaiser Health News Searching for a diagnosis: a network of doctors tries to solve medical mysteries
Pharmalot By Ed Silverman In a crafty move, FDA may have found a way to dampen controversy over a $375,000 rare-disease drug
Pharmalot By Ed Silverman Pharmalittle: FDA places hold on Novartis trial for gene therapy; FDA floats plan for combating shortages
Pharmalot By Ed Silverman Consumer groups urge Italian and Belgian authorities to investigate Biogen over Spinraza pricing
Pharmalot By Ed Silverman Catalyst sues FDA over rivals’ drug approval, warning it undermines incentives for rare disease meds
Pharmalot By Ed Silverman Jacobus prices its rare disease drug at half of what Catalyst charges, but will doctors prescribe it?
Biotech By Damian Garde and Adam Feuerstein Your guide to the mounting competition among new SMA drugs
Pharmalot By Ed Silverman Laura Jacobus hopes to provide her newly approved drug at ‘little or no’ cost to patients
Pharmalot By Ed Silverman Pharmalittle: Pfizer prices new rare disease drug at $225,000; Novartis pushes gene therapy
Pharmalot By Ed Silverman Pharmalittle: Appaloosa says Allergan moves are not enough; FDA rejects Sanofi diabetes pill
Pharmalot By Ed Silverman Pharmalittle: Pfizer pays $636 million for rights to gene therapies; Novartis denies bribing Greek officials
Pharmalot By Ed Silverman Catalyst says its pricey rare disease drug is doing ‘better than expected’ despite patient anger
Pharmalot By Ed Silverman Sanders asks FDA to allow sales of older versions of $375,000 rare-disease drug
Biotech By Jonathan Saltzman — Boston Globe Trials for potential ALS treatment using stem cells spark cautious hope
Pharmalot By Ed Silverman Parents accuse companies of stealing medical data from their very sick children
Pharmalot By Ed Silverman Rare diseases and trade secrets: Shire and Ultragenyx fight over lists of doctors
Business By Adam Feuerstein The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Biotech By Adam Feuerstein FDA rips into PTC’s Duchenne muscular dystrophy drug as advisory panel looms
Biotech By Damian Garde Key partner cuts ties with brash biotech startup Moderna, raising big questions about its pipeline
Biotech By Adam Feuerstein Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions
In the Lab By Sharon Begley In a medical first, ‘long read’ DNA sequencing solves a diagnostic mystery